STOCK TITAN

NeoGenomics (NEO) CAO exercises RSUs, surrenders shares for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

NeoGenomics Chief Accounting Officer Greg D. Aunan reported routine equity compensation activity involving restricted stock units and related tax withholding. On May 2, 2026, he exercised 5,372 restricted stock units into common stock and, in connection with vesting, surrendered shares to the company to satisfy tax obligations. The filings show 2,246 common shares disposed through issuer withholding across May 1 and May 2, 2026, and he now directly holds 25,153 shares of common stock. He also retains multiple unexercised stock option and RSU awards with exercise prices between $9.83 and $14.62 per share and expirations extending to 2036.

Positive

  • None.

Negative

  • None.
Insider Aunan Greg D
Role Chief Accounting Officer
Type Security Shares Price Value
Exercise Restricted Stock Unit 5,372 $0.00 --
Exercise Common Stock 5,372 $0.00 --
Tax Withholding Common Stock 1,309 $0.00 --
Tax Withholding Common Stock 937 $0.00 --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Restricted Stock Unit -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Restricted Stock Unit -- -- --
Holdings After Transaction: Restricted Stock Unit — 10,745 shares (Direct, null); Common Stock — 26,462 shares (Direct, null); Stock Option (Right to Buy) — 28,662 shares (Direct, null)
Footnotes (1)
  1. Shares surrendered to NeoGenomics, Inc. for retirement to satisfy tax obligations in connection with the May 1, 2026 vesting of restricted stock. Reflects the release of restricted stock units that were previously reported on a Form 4. Each restricted stock unit is economic equivalent of one share of NeoGenomics, Inc. common stock and is converted into common stock upon vesting. Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. On May 2, 2024, Mr. Aunan was granted 16,117 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. Once vested, the shares of common stock are not subject to expiration. On May 1, 2023, Mr. Aunan was granted 28,662 stock options. The options vest ratably over the first four anniversary dates of the grant date. On May 2, 2024, Mr. Aunan was granted 26,978 stock options. The options vest ratably over the first three anniversary dates of the grant date. On February 21, 2025, Mr. Aunan was granted 31,163 stock options. The options vest ratably over the first three anniversary dates of the grant date. On February 21, 2025, Mr. Aunan was granted 18,971 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. On March 1, 2026, Mr. Aunan was granted 36,825 stock options. The options vest ratably over the first three anniversary dates of the grant date. On March 1, 2026, Mr. Aunan was granted 22,889 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
RSUs exercised 5,372 shares Restricted stock units converted into common stock on May 2, 2026
Shares withheld for taxes 2,246 shares Tax-withholding dispositions on May 1 and May 2, 2026
Common shares held after transactions 25,153 shares Direct ownership following reported Form 4 activity
Option grant at $9.83 36,825 shares Stock options, exercise price $9.83, expiring March 1, 2036
Option grant at $11.86 31,163 shares Stock options, exercise price $11.86, expiring February 21, 2035
Option grant at $13.96 26,978 shares Stock options, exercise price $13.96, expiring May 2, 2034
Option grant at $14.62 28,662 shares Stock options, exercise price $14.62, expiring May 1, 2030
Outstanding RSUs 22,889 units Restricted stock units granted March 1, 2026, vesting over three years
Restricted Stock Unit financial
"On March 1, 2026, Mr. Aunan was granted 22,889 restricted stock units."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
economic equivalent financial
"Each restricted stock unit is economic equivalent of one share of NeoGenomics, Inc."
tax obligations financial
"Shares surrendered to NeoGenomics, Inc. for retirement to satisfy tax obligations in connection"
stock options financial
"On May 1, 2023, Mr. Aunan was granted 28,662 stock options."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
vest ratably financial
"The options vest ratably over the first three anniversary dates of the grant date."
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Aunan Greg D

(Last)(First)(Middle)
9490 NEOGENOMICS WAY

(Street)
FORT MYERS FLORIDA 33912

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
NEOGENOMICS INC [ NEO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Accounting Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/01/2026F937(1)D$021,090D
Common Stock05/02/2026M5,372(2)A$0(3)26,462D
Common Stock05/02/2026F1,309(4)D$025,153D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit$005/02/2026M5,372 (5) (6)Common Stock5,372$010,745D
Stock Option (Right to Buy)$14.62 (7)05/01/2030Common Stock28,66228,662D
Stock Option (Right to Buy)$13.96 (8)05/02/2034Common Stock26,97826,978D
Stock Option (Right to Buy)$11.86 (9)02/21/2035Common Stock31,16331,163D
Restricted Stock Unit$0 (10) (6)Common Stock12,64812,648D
Stock Option (Right to Buy)$9.83 (11)03/01/2036Common Stock36,82536,825D
Restricted Stock Unit$0 (12) (6)Common Stock22,88922,889D
Explanation of Responses:
1. Shares surrendered to NeoGenomics, Inc. for retirement to satisfy tax obligations in connection with the May 1, 2026 vesting of restricted stock.
2. Reflects the release of restricted stock units that were previously reported on a Form 4.
3. Each restricted stock unit is economic equivalent of one share of NeoGenomics, Inc. common stock and is converted into common stock upon vesting.
4. Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
5. On May 2, 2024, Mr. Aunan was granted 16,117 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
6. Once vested, the shares of common stock are not subject to expiration.
7. On May 1, 2023, Mr. Aunan was granted 28,662 stock options. The options vest ratably over the first four anniversary dates of the grant date.
8. On May 2, 2024, Mr. Aunan was granted 26,978 stock options. The options vest ratably over the first three anniversary dates of the grant date.
9. On February 21, 2025, Mr. Aunan was granted 31,163 stock options. The options vest ratably over the first three anniversary dates of the grant date.
10. On February 21, 2025, Mr. Aunan was granted 18,971 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
11. On March 1, 2026, Mr. Aunan was granted 36,825 stock options. The options vest ratably over the first three anniversary dates of the grant date.
12. On March 1, 2026, Mr. Aunan was granted 22,889 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
Remarks:
/s/ Ali Olivo, Attorney-in-Fact05/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did NeoGenomics (NEO) report for Greg D. Aunan?

NeoGenomics reported that CAO Greg D. Aunan exercised 5,372 restricted stock units into common stock and had 2,246 shares withheld to cover tax obligations. After these routine compensation-related transactions, he directly holds 25,153 shares of NeoGenomics common stock.

Were Greg D. Aunan’s NeoGenomics (NEO) share dispositions open-market sales?

No, the dispositions were not open-market sales. Footnotes state the shares were surrendered to NeoGenomics and withheld by the issuer to satisfy tax obligations related to vesting and release of restricted stock units, a standard non-market tax-withholding mechanism.

How many NeoGenomics (NEO) shares does Greg D. Aunan hold after these Form 4 transactions?

Following the reported Form 4 transactions, Greg D. Aunan directly owns 25,153 shares of NeoGenomics common stock. This figure reflects the net position after exercising 5,372 restricted stock units and the issuer’s withholding of 2,246 shares for related tax obligations.

What equity awards in NeoGenomics (NEO) remain outstanding for Greg D. Aunan?

Greg D. Aunan retains several equity awards, including stock options and restricted stock units. Outstanding options cover 36,825 shares at $9.83, 31,163 shares at $11.86, 26,978 shares at $13.96, and 28,662 shares at $14.62, with expirations ranging from 2030 to 2036.

How many NeoGenomics (NEO) shares were withheld for Greg D. Aunan’s tax obligations?

A total of 2,246 common shares were withheld for tax obligations, via two Form 4 transactions coded “F.” One covered 937 shares on May 1, 2026, and another covered 1,309 shares on May 2, 2026, both tied to restricted stock vesting and release.